BACK

Tom Babich

Tom Babich

Head of Capital Markets

New York Office  |  tom.babich@torreya.com   |   212.257.5811

Tom Babich, Head of Capital Markets at Torreya, leads funding transactions in the United States, including private equity investments, debt placements and royalty monetizations. He also has experience working on asset divestitures, mergers, and company sales.

Notable transactions on which Tom has worked include the Scidose, Opiant, and Xoma royalty sales in 2016; the New Mountain Capital majority equity investment in Topix Pharmaceuticals; and debt raises for Crown Labs, Amerigen, PDI, and Trimel.

Tom joined Torreya in 2009. Previously, he was a professional baseball player.

He received a B.A. in economics from Harvard University.

Tom is a director of Noria Therapeutics and is active with New York Cares and the Xaverian Brothers Alumni Association.

Selected Transactions

XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
Opiant Pharmaceuticals
Sale of royalties to
SWK Holdings
$17.5 million
December 2016
SciDose
Partial sale of royalty
and milestones
Undisclosed
$40 million
September 2016
Topix Pharmaceuticals
Sale of majority stake to
New Mountain Capital
Undisclosed
July 2016
Crown Laboratories
Debt financing from
Hayfin Advisors
$20 million
September 2015
Tris
Debt Recapitalization and Acquisition of NextWave Pharmaceuticals from
Pfizer
$125 million
September 2018
Standard Homeopathic Company
Term Loan from
Hayfin
$40 Million
June 2018
EyePoint Pharmaceuticals
Debt financing for acquisition of Icon Biosciences from
SWK Holdings
$20 Million
March 2018
Undisclosed Physical Therapy Practice
Majority recap by
Hildred Capital Partners
Undisclosed
March 2018
BIO-PHARM
Sale to
torrent pharma
Undisclosed
January 2018
Midatech
Loan agreement with
Midcap Financial
$15 Million
January 2018
Crown Laboratories
Sale of
majority equity stake to
Hildred
Undisclosed
December 2017
CombiMatrix
Merger with
Invitae Corporation
$34.9 million
November 2017
XOMA
License of
Gevokizumab and
certain associated IP to
Novartis
$31 million upfront
August 2017
Clarus Ventures
Acquisition of phase III royalty interest
Undisclosed
Undisclosed
May 2017
IntelgenX
Partial royalty and milestone sale to
SWK Holdings
$6 million
August 2016
Academic Investor
Sale of
phase II enzyme replacement royalty
Undisclosed
Undisclosed
August 2016
HealthCare Royalty Partners
Royalty-backed
acquisition financing
for undisclosed
spec pharma
Undisclosed
$100 million
February 2016
Amerigen
Senior term loan
Undisclosed
$15 million
December 2015
XOMA
Sale of
biologics manufacturing
facilities to
Agenus
$5 million in cash +
$1 million in stock
November 2015
PDI
Acquisition financing
from
SWK Holdings
$20 million
October 2014
ABT Molecular Imaging
Synthetic royalty
financing from
SWK Holdings
$10 million
October 2014
Trimel Pharmaceuticals
Loan from
MidCap Financial
$25 million
July 2014
Compugen
Financial advisor on
follow-on offering
Undisclosed
$72.5 million
February 2014
Canterbury Laboratories
Merger into
Restorgenex
Undisclosed
September 2013
Molecular Insight
Sale for up to
$106 million to
Progenics
$12 million +
milestones
January 2013
Xanodyne
Sale of
Amicar® rights to
Versapharm
Undisclosed
August 2012
Xanodyne
Sale of
Roxicodone® to
Covidien
Undisclosed
August 2012
Xanodyne
Sale of Zipsor® to
Depomed
Undisclosed
June 2012
Hedge Fund
Structured debt transaction linked to
three pharma royalties
Pharmakon
$65 million
December 2011
Ventrus Biosciences
Financial advisor in
follow-on financing
for GI company
Undisclosed
Undisclosed
July 2011
Aegera Therapeutics
Sale of Canadian biotechnology
company to
Pharmascience
Undisclosed
May 2011
Xanodyne
Co-promotion for
Zipsor®
Medimetriks
Undisclosed
May 2011
Hedge Fund
Sale of
royalties for Cubicin®
and Lexiscan® to
Royalty Pharma
$487 million
April 2011
DNP
Acquisition of
Thorne Research
$40 million +
milestones
June 2010